Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aptuit, which focuses on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators, has appointed Timothy Tyson as its new executive chairman and acting CEO.
Subscribe to our email newsletter
Michael Griffith, the company’s founder and CEO since 2005, has resigned in order to pursue other opportunities.
Mr Tyson is the former COO, president and CEO of Valeant Pharmaceuticals. Prior to Valeant, Tyson’s pharmaceutical industry experience includes 14-year tenure at GlaxoSmithKline, where he was president of global manufacturing and supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals.
Tony Ecock, outgoing chairman of board of managers at Aptuit, said: “The board wishes to thank Mike for his outstanding success in creating a world-class organization that is a trusted partner to hundreds of innovative clients throughout the world.”